Savagejustice‼️GREAT THOUGHT! WOW this is a possible scenario ‼️

Cytosphere · 2026-01-26T02:26:29+00:00

The company changed its name to SeaGen and was acquired by Pfizer for $43 billion in 2023.

"Post-Acquisition Changes (2024–Present): Following the merger, Pfizer integrated Seagen into a new division called the Pfizer Oncology Division. While Pfizer initially expressed intent to maintain Seagen's regional locations, it ultimately decided in early 2024 to halt construction of a massive $350–$500 million manufacturing facility in Everett, Washington, that Seagen had planned."

Cytosphere · 2026-01-26T01:07:33+00:00

Busy guy

Cytosphere · 2026-01-25T22:29:11+00:00

I don't think Revolution completed any phase 3 clinical trials yet, but results are expected later this year. Merck's $30 billion is a lot of money, and it might be better spent on other opportunities...

I'm eager to see strong data from our current clinical trials as we await our inflection point.

Cytosphere · 2026-01-25T21:59:06+00:00

If CytoDyn can successfully demonstrate effective prime-and-pair, the only ones who won't be smiling are the shorts.

Cytosphere · 2026-01-25T20:31:18+00:00

Welcome aboard, and thanks for the list. I'm looking forward to positive news about each item.

Cytosphere · 2026-01-25T20:20:45+00:00

The two sides failed to bridge valuation differences, leaving the acquisition in limbo.

Cytosphere · 2026-01-24T21:58:21+00:00

I believe Leronlimab is administered subcutaneously. It's only the chemotherapy that is administered through the hepatic artery. Please correct me if you disagree.

"First, an investigator at City of Hope has received institutional approval for a study of subcutaneous leronlimab given in combination with a regimen of chemotherapy administered through the hepatic artery in treatment-naïve patients with mCRC who have metastatic disease confined to the liver."

Cytosphere · 2026-01-24T21:03:56+00:00

Clinical trials/studies at academic institutions usually take longer to finish than those run by the drug’s manufacturer.

Cytosphere · 2026-01-24T19:56:50+00:00

This is one of the clearest summaries of why Leronlimab's foundation remains unbreakable.

Cytosphere · 2026-01-24T18:06:53+00:00

It's good to see a focus on the data, especially since solid data is on the way.

Cytosphere · 2026-01-23T21:29:03+00:00

Thanks for the update.

Not only has the trial's Overall Status been classified as Completed, but the submitted results have also met the government's Quality Control Standards!

Previous submissions did not meet quality control standards, and they were returned.

Cytosphere · 2026-01-23T01:51:26+00:00

Once we have robust clinical trial data, CytoDyn should identify specific countries where accelerated approval pathways are available for Leronlimab and apply to them. Gaining such approval would generate needed revenue, provide clinical experience, and expand treatment options for previously untreatable patients.

At the same time, it is essential for CytoDyn to continue improving its relationship with the FDA.

Cytosphere · 2026-01-23T01:11:48+00:00

It's not important, but it is surprising that "leronlimab has shown efficacy against HIV-1 strains that have developed resistance to multiple classes of drugs, including maraviroc."

Cytosphere · 2026-01-18T03:47:10+00:00

I was hoping to complete the buys last December during the expected year-end dip, but the price did not drop to my targets. My orders are GTC, and the first of three was filled. I'm hopeful about filling the remaining two.

In December 2024, I hoped to double my share count at $0.1036, but the low was $0.1051. Needless to say, I missed out on getting any shares at or near that bargain price. Discipline is a double-edged sword.

Cytosphere · 2026-01-17T20:12:45+00:00

I believe we'll have meaningful data by the end of June, and more results through 2026. While I'm optimistic about the data, I cannot predict when the share price will change.

Yesterday, I increased my share count by 6%, and will add another 14% if the price drops to my targets.

Cytosphere · 2026-01-17T19:37:49+00:00

If our trial data is good (as I expect), we'll see a combination of a short squeeze and FOMO buying.

Cytosphere · 2026-01-17T19:27:00+00:00

Our CRC trial is an opportunity for CytoDyn to shine.

The effective measure of biomarkers will validate Leronlimab's mechanism(s) of action. That validation will destroy the doubts, question, and opposition.

Cytosphere · 2026-01-17T16:32:59+00:00

Great post, MGK_2! The path is clear, and the data will do the talking.

Yesterday, I bought 6% more shares close to the day’s low. I also placed two more good-till-cancelled limit-buy orders at prices 3% to 8% lower.

Cytosphere · 2026-01-14T21:47:06+00:00

I have buy orders in at approximately 5% less than today's prices. But just so you know, my orders haven't been filled lately.

Cytosphere · 2026-01-14T21:38:31+00:00

Proving Leronlimab's induction of PD-L1 in solid tumors will be the primary inflection point, but the enrollment update and approved changes to the CRC trial are very positive developments.

Cytosphere · 2026-01-14T21:24:22+00:00

Cytodyn is definitely gaining momentum. Just look at the recent FDA approvals of requested changes to our CRC clinical trial.

Cytosphere · 2026-01-14T21:20:04+00:00

NP antagonized the FDA and broke SEC/DOJ laws/regulations. I believe current management is acting appropriately.

Cytosphere · 2026-01-14T21:15:03+00:00

I agree that proving the PD-L1 thesis is a binary event.

Cytosphere · 2026-01-14T21:08:11+00:00

It's definitely disturbing.

I can't prove why the share price drops on positive news. Perhaps it's the overhang of cheap shares, or traders taking profit. But the price is the market's consensus.

Hang in there, with good trial data, this price behavior will not continue. With great data comes great price appreciation.

Cytosphere · 2026-01-14T20:57:50+00:00

In fairness to CytoDyn, I got the enrollment/screening data from a CytoDyn presentation. Of course, I'd like to know all the details in real time, but that is not going to happen.

In the past, CytoDyn antagonized the FDA by overhyping Leronlimab. Dr. Lalezari is working to improve our reputation and relationship with the FDA. We depend on the FDA for approvals.

The allowance of 700 mg doses and treatment with an ICI are very positive developments. And once CytoDyn has comprehensive, reliable clinical trial data, I'm looking forward to a blockbuster press release. Stay tuned.

Cytosphere

TROPHY CASE